BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Alexion Pharmaceuticals Inc. 

352 Knotter Drive

Cheshire  Connecticut  06410  U.S.A.
Phone: 203-272-ALXN Fax: 203-271-8198


View Clinical Trials from BioPharm Insight

Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.

Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.

Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.

Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).

Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.

 Key Statistics

Ownership: Public

Web Site: Alexion
Employees: 1,500
Symbol: ALXN



 Company News
200 Jobs Promised at Alexion (ALXN) Amid €450 Million Expansion 5/11/2015 6:38:31 AM
Alexion (ALXN) Investors May (In Time) Love Lofty Biotech Bid 5/7/2015 7:18:39 AM
Alexion (ALXN) Release: Researchers Present New Data From Phase 2 Clinical Trial Of Eculizumab (Soliris) In Prevention Of Acute Antibody-Mediated Rejection (AMR) In Sensitized Deceased-Donor Kidney Transplant Recipients 5/6/2015 9:52:26 AM
Alexion (ALXN) Plunks Down $8.4 Billion for Synageva BioPharma (GEVA), As Dealmaking Roars 5/6/2015 5:50:36 AM
Alexion (ALXN) To Present At Investor Conferences 4/29/2015 12:33:10 PM
Alexion (ALXN) Reports First Quarter 2015 Results 4/23/2015 11:30:21 AM
Alexion (ALXN) Announces Presentations At 2015 American Transplant Congress, Including Results From Studies Advancing The Understanding Of Eculizumab (Soliris) In Patients Undergoing Kidney Transplant 4/13/2015 8:22:17 AM
Alexion (ALXN) Receives Approval For Important Updates To The European Label For Soliris (Eculizumab) 4/10/2015 11:44:11 AM
With Alexion (ALXN) Deal in Hand, Blueprint Medicines Preps for $100 Million IPO 3/24/2015 6:06:57 AM
Alexion Pharmaceuticals Inc. (ALXN) Release: New Data From First Natural History Study In Juveniles With Hypophosphatasia (HPP) Showing Substantial Disease Burden, Including Musculoskeletal Abnormalities And Growth Deficiencies, Presented In Late-Breaking Oral Session At ENDO 2015 3/9/2015 11:38:35 AM